Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096862 · ClinicalTrials.gov registry record · Phase 2
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2 study of Psoriasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 11
- Study locations
NCT01096862: Completed Phase 2 study of Psoriasis, sponsored by Astellas Pharma.
NCT01096862 is a Phase 2 study of Psoriasis that has completed, run by Astellas Pharma. The registered enrollment target is 124 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (75% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01096862, a Phase 2 study of Psoriasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG peficitinib
Study Locations (11)
Florida
- FXM Research, Corp. - Miami
- Renstar Medical Research - Ocala
Alabama
- Total Skin & Beauty Dermatology Center - Birmingham
California
- Therapeutics Clinical Research - San Diego
Kentucky
- Derm Research, PLLC - Louisville
Oregon
- Oregon Medical Research Center - Portland
South Carolina
- Palmetto Clinical Trial Services - Greenville
Tennessee
- Rivergate Dermatology - Goodlettsville
Texas
- J & S Studies - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2010-03-23 |
| Est. Completion | 2011-07-27 |
| Phase | Phase 2 |
What the finished NCT01096862 record still lists
NCT01096862 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01096862 lists 11 locations in 10 states (Florida, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT01096862 about?
NCT01096862 is a clinical study titled "A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis". The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT01096862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2010-03-23. Estimated completion is 2011-07-27.
What conditions does trial NCT01096862 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01096862?
The interventions under investigation include: Placebo (DRUG), peficitinib (DRUG).
Who is sponsoring clinical trial NCT01096862?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01096862 being conducted?
This trial has 11 study locations across Alabama, California, Florida, Kentucky, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01096862's enrollment target sits among peer trials
124 53rd of 125 higher than 73 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI